Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) (HD0607)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2012 by Ospedale Santa Croce-Carle Cuneo
Sponsor:
Collaborators:
GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)
Consorzio Mario Negri Sud
Information provided by (Responsible Party):
DR. ANDREA GALLAMINI, Ospedale Santa Croce-Carle Cuneo
ClinicalTrials.gov Identifier:
NCT00795613
First received: November 19, 2008
Last updated: February 2, 2012
Last verified: February 2012
  Purpose

The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.


Condition Intervention Phase
HODGKIN LYMPHOMA
Drug: ESCALATED BEACOPP
Drug: CONVENTIONAL ABVD
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses

Resource links provided by NLM:


Further study details as provided by Ospedale Santa Croce-Carle Cuneo:

Primary Outcome Measures:
  • progression-free survival (PFS) [ Time Frame: 3 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • event-free survival (EFS) [ Time Frame: 3 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 450
Study Start Date: June 2008
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PET pos
Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
Drug: ESCALATED BEACOPP
Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
Other Names:
  • BLEOMICINE TEVA
  • VEPESID
  • DOXORUBICINE TEVA
  • ENDOXAN
  • VINCRISTINE TEVA
  • NATULAN
  • DELTACORTENE
  • MABTHERA
PET negative
Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
Drug: CONVENTIONAL ABVD
ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
Other Names:
  • BLEOMICINE TEVA
  • DOXORUBICINE TEVA
  • VELBE
  • NATULAN

  Hide Detailed Description

Detailed Description:

Version number 1.0 Date 07.05.0808

Study Title

A phase-II clinical trial for assessing the clinical impact of a global strategy utilizing early FDG-PET imaging for a risk-adapted therapy in untreated, advanced Hodgkin Lymphoma (aHL).

Short study title PET-adapted chemotherapy in advanced HL

Start and end dates of study Start date: July 2008

Patients will be recruited during four calendar years and will be followed at least for three years.

Registration of the patients All patients with newly diagnosed Hodgkin's Lymphoma, presenting with advanced disease (stage II B-IV B) should be registered at the WEB site of the study whatever treatment is planned.

Primary outcome measure 3-year progression free survival (PFS).

Secondary endpoint 3-year event free survival (EFS) of all the registered patients whatever the treatment assigned. Events are deaths from any cause, disease progression, secondary cancer, late serious treatment-related events.

- Feasibility of the program for the entire population of advanced-stage HL patients admitted to GITIL institutions

Clinical Phase Phase II

Study design A multicentre clinical trial for assessing the clinical impact of a global strategy utilizing early FDG-PET imaging after 2 cycles of ABVD for a risk-adapted, single patient tailored therapy for all the newly diagnosed, aHL patients admitted to GITIL haematological centers .

Statistical aspects 450 patients could be recruited in GITIL centres in 4 years. Thirty-five percent of these could be expected to have a PET-2 positive after 2 ABVD courses (135 patients). Roughly half of these latter could likely be salvaged by BEACOPPescal. or R-BEACOPPescal. therapy. Since the 3-y PFS of aHL patients treated with the ABVD is 70% we could expect to cure, with this approach, about 85% of these patients. In order to demonstrate a benefit of this strategy over conventional ABVD treatment, with the Simon optimal two-stage design and an alpha error of 0.05 and a power of 90%, a minimum of 150 patients needs to be enrolled. In order to establish an advantage of R-BEACOPP esc. over BEACOPPescal. Approximately 135 patients are needed in the arm of PET-positive patients.

Analysis will be intention-to-treat. Standard time-to-event statistics tests will be carried out, including Kaplan-Meier survival curves, log rank test, and Cox proportional hazards models. Chi square test and analysis of variance will be adopted for univariate analysis with mathematical transformation to approach normality as appropriate. The formal level of significance for P-values is set at 0.05 (two-tailed).

Interim analysis and safety aspects A first interim analysis is planned one year after study onset in order to check the morbidity and mortality of the program. Because of the rarity of the disease, no formal statistical boundaries are established as stopping rules. The results of the interim analysis will be evaluated by the Data Safety and Monitoring Board (DSMB). The Chairman of the DSMB will advise the Steering Committee (ST) as to the any action to be taken for safety reasons (i.e., premature study closure and protocol modification). The DSMB will also establish and communicate to the ST and the CRO its own rules and requirements to optimize the quantity and quality of information to be periodically received to monitor adequately all safety aspects.

Initial treatment for 2 cycles ABVD (cycle repeats every 28 days) This will be given at full dose and on schedule, regardless of blood count. Growth factors may be used at the discretion of investigators but are not routinely advised.

PET Reviewing Committee A central panel for PET reviewing (PET-RC) will be established. The members will be seven nuclear medicine experts. The operational aspects of the validation of PET diagnoses will be managed by the National Institute of Nuclear Physics in Turin using an already existing and functioning web-site. Upon receipt of PET-2 records, along with PET baseline studies via web, the PET-RC members are bound to send the reviewed studies to the Central Data Center (CDC) within 5 days from the data of receipt of the studies from the local PET enter. The image exchange will be performed by uploading the records of PET-2 (PET after 2 cycles of ABVD) and PET-0 (baseline PET) in the .dycom format in the web site dedicated.Only the positive and "minimally positive" PET scan will be reviewed. The final judgment of a reviewed defined as "positive" or "negative" study will be supplied from the CDC to the local GITIL center on the basis of the first three reviewed studies arrived to CDC

After 2 cycles, PET negative patients (Arm B) continue with ABVD (for 4 cycles) ABVD as above, every 28 days for 4 further cycles Patients in Arm B with a positive PET at the end of ABVD treatment. Patients with a positive PET at the end of ABVD chemotherapy should undergo, whenever is possible, a confirmatory biopsy; in patients with a proven resistant disease DHAP (x1 or x2) should be given in order to collect a sufficient number of CD 34+ cells; later they proceed to a classical high-dose sequential chemotherapy (HDS) with: cyclophosphamide 4 gr./m2 , ARA-c 4 gr./m2/day for 4 days, VP 16 2 gr./m2, followed by autologous stem cell transplantation (ASCT) with BEAM conditioning regimen

Consolidation Radiotherapy (Arm B) Patients treated with traditional ABVD x 6 cycles (PET-negative arm) will be re-evaluated at the end of chemotherapy with PET. Patients with a negative final PET scan will be randomized to undergo consolidation radiotherapy or not on the initial bulky lesion(s) or on the residual disease. Radiotherapy will be given with an "involved field technique, at the dose of 30 Gy. No radiotherapy is planned in patients with residual mass that was not an initial bulky lesion.

After 2 cycles, PET positive patients (Arm A) will be randomized to 4 escalated BEACOPP or 4 escalated R-BEACOPP administration for 4 cycles. Peripheral Blood Stem Cell (PBSC) will be collected after the first BEACOPP (or R-BEACOPP) course

After 4 cycles of escalated BEACOPP or escalated R-BEACOPP patients with PET negative will continue with baseline BEACOPP or baseline R-BEACOPP (for further 4 cycles )

After 4 cycles of escalated BEACOPP or escalated R-BEACOPP patients with positive PET will undergo salvage treatment with DHAP (x 1 or x 2) followed by double autologous stem cell transplantation (ASCT) or, in presence of a suitable HLA-matched stem cell donor, with a single ASCT (BEAM) followed by RIC allogeneic bone marrow transplantation .

Allogeneic Reduced-Intensity transplant:

Thiotepa 5 mg/Kg every 12 hours for 2 doses (day -5); cyclophosphamide 30 mg/kg (days -4 and -3); fludarabine 30 mg/ms (days -4 and -3); allogeneic stem cell transplantation with 4 - 8 X 106 CD34+ cells/kg from related donors (day 0).

GVHD prophylaxis:

Cyclosporin A (CSA), adjusted to 200-300 ng/ml blood levels, and short course methotrexate (10 mg/ms day +1, 8 mg/ms day + 3 and +6). CSA is administered at full dose through day +100 and, if GVHD does not occur, the dose is tapered by 10% every week thereafter

Treatment duration Approx 10-11 months for PET-2+ patients and 6 months for PET-2 negative patients

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with advanced classical Hodgkin Lymphoma according to the World Health Organization classification
  • Aged 18-60
  • Not previously treated
  • Stages IIB to IV B
  • All IPS prognostic groups
  • Patients who have signed an informed consent form

Exclusion Criteria:

  • Patients aged more than 60.
  • Concomitant or previously treated neoplastic disorder less than 5 year before the diagnosis of Hodgkin's lymphoma.
  • Psychiatric disorders
  • Uncontrolled infectious disease
  • Impaired cardiac (EF < 50%) , renal (creatinine clearance < 60 ml/m)
  • HIV, HBV DNA, HCV RNA positive markers
  • Pregnancy and lactation
  • Patients with uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00795613

Contacts
Contact: ANDREA GALLAMINI, MD +39 0171 642414 gallamini.a@ospedale.cuneo.it
Contact: MARIA R. MENNITTO, PHARMACIST +39 0872 570250 HD0607@negrisud.it

Locations
Israel
The Chaim Sheba Medical Center Recruiting
Tel Hashomer, Israel
Contact: ABRAHAM AVIGDOR, MD         
Principal Investigator: ABRAHAM AVIGDOR, MD         
Italy
Ospedale S. Gerardo Recruiting
Monza, Milano, Italy, 20052
Principal Investigator: ENRICO POGLIANI, MD         
A.O. Universitaria S. Luigi Gonzaga Recruiting
Orbassano, Torino, Italy, 10043
Principal Investigator: GIUSEPPE SAGLIO, MD         
A.O. Universitaria Ospedali Riuniti Osp. Umberto I Recruiting
Ancona, Italy, 60100
Principal Investigator: PIETRO LEONI, MD         
Ospedali Riuniti Recruiting
Bergamo, Italy, 24128
Principal Investigator: RAMBALDI ALESSANDRO, MD         
Ospedale Generale Regionale Bolzano Recruiting
Bolzano, Italy, 39100
Principal Investigator: SERGIO CORTELAZZO, MD         
Ospedale Roberto Binaghi Recruiting
Cagliari, Italy, 09126
Principal Investigator: GIORGIO LA NASA, MD         
A.O. Universitaria Osp. Vittorio Emanuele E Ferrarotto Recruiting
Catania, Italy, 95124
Principal Investigator: FRANCESCO DI RAIMONDO, MD         
Azienda Ospedaliera S. Croce E Carle Recruiting
Cuneo, Italy, 12100
Contact: ANDREA GALLAMINI, HEM DEP HEAD    +39 0171 642414    gallamini.a@ospedale.cuneo.it   
Sub-Investigator: CLAUDIA CASTELLINO, MD         
Sub-Investigator: FRANCESCA FIORE, MD         
Principal Investigator: ANDREA GALLAMINI, MD         
Azienda Ospedaliera Universitaria S. Martino Recruiting
Genova, Italy, 16126
Principal Investigator: MARCO GOBBI, MD         
Irccs - Istituto Nazionale Dei Tumori (Int) Recruiting
Milano, Italy, 20133
Principal Investigator: PAOLO CORRADINI, MD         
Ospedale S. Raffaele Turro Recruiting
Milano, Italy, 20127
Principal Investigator: FABIO CICERI, MD         
Irccs Istituto Nazionale Dei Tumori (Int) Recruiting
Milano, Italy, 20133
Principal Investigator: ALESSANDRO MA GIANNI, MD         
A.O. Universitaria Federico Ii Recruiting
Napoli, Italy, 80131
Principal Investigator: FABRIZIO PANE, MD         
Azienda Ospedaliera Recruiting
Padova, Italy, 35127
Principal Investigator: GIAMPIETRO SEMENZATO, MD         
Azienda Ospedaliera V. Cervello Recruiting
Palermo, Italy, 90146
Sub-Investigator: CATERINA PATTI, MD         
Principal Investigator: MIRTO SALVO, MD         
Ospedale Silvestrini-S.Andrea Delle Fratte Recruiting
Perugia, Italy, 06156
Principal Investigator: LEONARDO FLENGHI, MD         
Ospedale S. Carlo Recruiting
Potenza, Italy, 85100
Principal Investigator: ATTILIO OLIVIERI, MD         
A.O. Universitaria Policlinico Tor Vergata Recruiting
Roma, Italy, 00133
Principal Investigator: SERGIO AMADORI, MD         
Azienda Ospedaliera San Camillo-Forlanini Recruiting
Roma, Italy, 00149
Principal Investigator: IGNAZIO MAJOLINO, MD         
A.O. Universitaria S. Giovanni Battista-Molinette Recruiting
Torino, Italy, 10134
Principal Investigator: PAOLO GAVAROTTI, MD         
Ospedale Mauriziano Umberto I Recruiting
Torino, Italy, 10128
Principal Investigator: CORRADO TARELLA, MD         
Ospedale Policlinico G.B. Rossi Recruiting
Verona, Italy, 37134
Principal Investigator: GIOVANNI PIZZOLO, MD         
Ospedale Di Vicenza Recruiting
Vicenza, Italy, 36100
Principal Investigator: FRANCESCO RODEGHIERO, MD         
Sponsors and Collaborators
Ospedale Santa Croce-Carle Cuneo
GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)
Consorzio Mario Negri Sud
Investigators
Study Chair: ANDREA GALLAMINI, MD A.S.O. S.CROCE E CARLE-HEMATOLOGY DEPT. - VIA M. COPPINO 26-12100 CUNEO ITALY
  More Information

Additional Information:
Publications:
Responsible Party: DR. ANDREA GALLAMINI, HEAD OF HAEMATOLOGY DEPT. A.S.O. S. CROCE AND CARLE, Ospedale Santa Croce-Carle Cuneo
ClinicalTrials.gov Identifier: NCT00795613     History of Changes
Other Study ID Numbers: GITIL - HD0607
Study First Received: November 19, 2008
Last Updated: February 2, 2012
Health Authority: Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by Ospedale Santa Croce-Carle Cuneo:
PET

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Doxorubicin
Liposomal doxorubicin
Procarbazine
Vincristine
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators

ClinicalTrials.gov processed this record on August 27, 2014